WO1999016786A1 - Utilisation de composes de saponine et de steroides pour prevenir la senilite et nouveaux composes de saponine steroide - Google Patents
Utilisation de composes de saponine et de steroides pour prevenir la senilite et nouveaux composes de saponine steroide Download PDFInfo
- Publication number
- WO1999016786A1 WO1999016786A1 PCT/CN1998/000204 CN9800204W WO9916786A1 WO 1999016786 A1 WO1999016786 A1 WO 1999016786A1 CN 9800204 W CN9800204 W CN 9800204W WO 9916786 A1 WO9916786 A1 WO 9916786A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glu
- gal
- compound
- formula
- glucopyranosyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to steroidal saponin compounds for preventing and treating senile dementia (such as Alzheimer's dementia, vascular dementia, and other types of dementia), new steroidal saponin compounds, and pharmaceutical compositions containing them.
- senile dementia such as Alzheimer's dementia, vascular dementia, and other types of dementia
- new steroidal saponin compounds such as Alzheimer's dementia, vascular dementia, and other types of dementia
- pharmaceutical compositions containing them such as Alzheimer's dementia, vascular dementia, and other types of dementia
- Alzheimer's disease is a multiple disease of the elderly, and is a group of unexplained progressive mental disorders in neurology. Alzheimer's dementia
- Alzheimer's Disease Alzheimer's Disease
- vascular dementia mixed and other types of dementia.
- the prevalence of senile dementia in foreign countries accounts for 3-8% of the elderly over 65 years old, and as high as 20% of the elderly over 80 years old.
- the results of a recent Alzheimer's survey conducted in collaboration between Shanghai and the United States show that the overall prevalence of dementia among people aged 65 and older in Shanghai is 4.36%.
- the life expectancy of human beings has been extended, countries in the world will enter the aging society, and the number of patients will increase greatly. Alzheimer's has become an urgent medical and social problem.
- cholinesterase inhibitors such as tetrahydroaminoacridine and huperzine A
- vasodilators such as ergotin
- calcium channel blockers such as Nimodipine
- Steroidal saponins are a class of oligoglycosides derived from spirostane compounds. Steroidal saponins are widely distributed in the plant kingdom, both in monocotyledons and cotyledons, especially in plants such as Dioscoreaceae, Liliaceae, Scrophulariaceae, Polygonaceae, Agaveceae, etc.
- Steroid Ghost Wu is famous for its aglycones as raw materials for synthetic contraceptives and hormone drugs, which is more important than its direct use as a medicinal product.
- steroid saponins have antitumor, hypoglycemic, immunomodulatory, cholesterol, antibacterial, prevention of cardiovascular disease activity, such as re-building of traditional Chinese medicine saponin I and saponins IV of P 388, L-1210, KB cells It has cytotoxic effect; Pseudo-grilled saponin ⁇ and timosaponin ⁇ in the saplings of the sclerotium have hypoglycemic effect on oral administration of tetrahydropyridine diabetes model and streptozotocin diabetes model mice; Saponins can increase the immune function of mice; former Soviet researchers found that steroidal saponins can reduce cholesterol, and spirosaponin is more active than furostatin; Activity; Dioscorea zingiberensis water-soluble saponins can reduce angina pectoris, regulate metabolism, and effectively treat coronary heart disease.
- Object of the invention
- the object of the present invention is to provide a new class of drugs for preventing and treating senile dementia, which have excellent curative effect and low side effects.
- the steroidal saponins represented by the following formula I can expand the cerebral basal artery and improve cerebral circulation metabolism; can significantly increase the number of nicotinic acetylcholine receptors (N receptors); Can promote nerve cell growth; can scavenge free radicals.
- N receptors nicotinic acetylcholine receptors
- the compound of the present invention can effectively increase the number of N receptors, its action intensity is similar to that of nicotine, and it has a dose-effect relationship.
- the compound of formula I can be used as a medicine for preventing and treating dementia.
- the present invention has been completed based on the above findings.
- the first aspect of the present invention relates to steroidal saponin compounds of the general formula (I) and stereoisomers thereof for preventing and treating senile dementia.
- Ri is hydrogen, -OH, -O-Xyl, -O-Ara-Rha, -O-Fuc-Rha, -O-Ara-
- R 2 is hydrogen, -OH, -O-Fuc, -O-Rha, or -O-Glu;
- t is hydrogen, -OH, or -OS0 3 Na
- R 5 is hydrogen, hydroxyl, -O-Glu, or is absent
- Ri4 is hydrogen, or -OH
- Ris is hydrogen, or -OH
- R 23 is hydrogen, or -OH
- X is ⁇ , or ⁇
- ⁇ is a straight key or does not exist
- Z is Glu or does not exist.
- the second aspect of the present invention relates to a new steroidal saponin compound represented by the general formula (II)
- R'i 5 is hydrogen
- R'2 is ⁇ -OH or ⁇ -OH
- R'2 is hydrogen
- R ' 3 is-O-Gal-Glu
- 11 '15 is 00-OH or ⁇ -OH
- R'2 is hydrogen
- R'IS is hydrogen
- C 25 is R, or S configuration
- R'3 is -O-Gal
- Rha -O-Glu 4 Rha
- Another aspect of the present invention relates to a pharmaceutical composition for preventing and treating senile dementia, which comprises a compound of general formula (I) as an active ingredient and a pharmaceutically acceptable carrier mixed therewith.
- Another aspect of the present invention relates to the use of a compound of general formula (I) in the manufacture of a medicament for the prevention and treatment of dementia in the elderly.
- Another aspect of the present invention relates to a method for preventing and treating senile dementia, which method comprises: administering a preventive and effective amount of a compound of the general formula (I) or a pharmaceutical composition containing the compound to a host in need thereof.
- Figure 1 shows the effect of compound III of the present invention on rat aortic contraction induced by KC1.
- Figure 2 shows the effect of Compound III of the present invention on cerebral blood flow in rats.
- Figure 3 shows the effect of Compound III of the present invention on the N receptor.
- Figure 4 shows the effect of Compound III of the present invention on the N receptor.
- the present invention first relates to a compound of general formula (I) and its stereoisomers for preventing and treating senile dementia,
- R 2 is hydrogen, -OH, -o-Fuc, -o-Rha, or -o-Glu;
- Rt is hydrogen, -OH, or -OS0 3 Na
- R 5 is hydrogen, hydroxyl, -O-Glu, or is absent
- Ri4 is hydrogen, or -OH
- R 15 is hydrogen, or -OH
- R 23 is hydrogen or -OH
- X is ⁇ or ⁇
- ⁇ is a straight key or does not exist
- Z is Glu or does not exist
- a further aspect of the present invention relates to a compound of general formula ( ⁇ )
- R'l5 is hydrogen
- R ' 2 is ⁇ -OH or ⁇ -OH
- R'3 is -O-Gal-Glu-Glu
- R'2 is hydrogen
- R ' 3 is-O-Gal-Glu
- 11 '15 is 00-OH or ⁇ -OH
- R'2 is hydrogen
- C 25 is R, or S configuration
- R ' 3 is -0-Gal
- R 27 -CH 3
- C 25 is S configuration
- X is 0,
- Z is - ⁇ -Glu
- Y is not present
- R 22 is not present
- C The 20- C 22 -position is a double bond, and the other two are single bonds.
- the compound of formula (I) is preferred among them.
- the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- R 5 aH, R 22 is not
- R 5 does not exist
- R 22 does not exist
- Y is a straight bond
- ZO does not exist
- R 3 is -0-P-Gal 4 -P-Glu 2 -p Glu, R 22 is absent,
- the C 5 _ 6 position ... is a double bond, the others ... are single bond compounds.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising, as an active ingredient, a compound of the general formula (I) or a stereoisomer thereof, and a pharmaceutically acceptable carrier mixed therewith.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the general formula (II) as an active ingredient and a pharmaceutically acceptable carrier mixed therewith.
- Still another aspect of the present invention relates to the use of a compound of general formula (I) or a stereoisomer thereof for the preparation of a medicament for preventing or treating a disease or symptom of senile dementia.
- the present invention also relates to a method for preventing or treating Alzheimer's disease or symptoms, which comprises administering a therapeutically effective amount of a compound of general formula (I) or a stereoisomer thereof to a patient in need of treatment.
- senile dementia refers to Alzheimer's disease, vascular dementia, mixed or other types of dementia.
- the compound of the general formula (I) or the general formula (II) of the present invention is derived from plants, such as Zhimu, Huang Yam, garlic, Zhonglou, Yuzhu, Ophiopogon, Fanma, and the like. It can be obtained by extraction from the above plants or by structural modification.
- Conventional pharmaceutical dosage forms made of compounds of the general formula (1) can be used as medicines.
- the formulation of the drug is formulated with commonly used diluents (such as fillers, loose fillers, adhesives, wetting agents, disintegrating agents, surfactants, lubricants) or excipients.
- the pharmaceutical preparation can be selected from various administration dosage forms according to the purpose of treatment. Typical administration forms are, for example, tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories, injection preparations (such as solutions, suspensions, etc.) and the like.
- various carriers known in the art can be widely used.
- excipients such as lactose, sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid, etc .
- binders such as water, ethanol, propanol, ordinary syrup, glucose solution , Starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, polyvinylpyrrolidone, etc .
- disintegrating agents such as dry starch, sodium alginate, agar powder, alginate, sodium bicarbonate , Calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, glyceryl monostearate, starch, lactose, etc .
- disintegration inhibitors such as white sugar, glyceryl tristearate, cocoa Absorption enhancers such as fats and hydrogenated oils, such as quaternary ammonium salts, sodium lauryl sul
- the tablet formulation can also be further made into tablets coated with conventional tablet coatings, such as sugar-coated tablets, gelatin film-coated tablets, enteric-coated tablets, film-coated tablets, or double-layer tablets and Multilayer tablets.
- conventional tablet coatings such as sugar-coated tablets, gelatin film-coated tablets, enteric-coated tablets, film-coated tablets, or double-layer tablets and Multilayer tablets.
- various carriers known in the art can be widely used.
- the carrier are, for example, excipients such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, kaolin, talc, etc .; binders such as powdered gum arabic, powdered tragacanth, gelatin, ethanol, etc.
- Disintegrants such as alginate, agar, etc .
- various carriers known in the art can be widely used.
- the carrier are, for example, polyethylene glycol, cocoa butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides, and the like.
- the active ingredient compound of the general formula (I) is mixed with the above-mentioned various carriers, and the mixture thus obtained is placed in a hard gelatin capsule or a soft capsule.
- a solution is prepared. Emulsions and suspensions are sterilized.
- preparations are preferably isotonic with blood, and all diluents commonly used in the art can also be used, such as water, ethanol, polyethylene glycol, 1,3-propanediol, ethoxy Isostearyl alcohol, poly-oxidized isostearyl alcohol, polyoxyethylene sorbitan fatty acid ester, and the like.
- diluents commonly used in the art can also be used, such as water, ethanol, polyethylene glycol, 1,3-propanediol, ethoxy Isostearyl alcohol, poly-oxidized isostearyl alcohol, polyoxyethylene sorbitan fatty acid ester, and the like.
- sodium chloride, glucose, or glycerol may be added to the preparation for injection, and conventional dissolving additives, buffers, local anesthetics, etc. may also be added.
- colorants, preservatives, flavors, flavoring agents, Sweeteners or other materials may be added.
- the content of the compound of the general formula (I) as an active ingredient is not particularly limited, and can be appropriately selected from a wide range.
- the method of administering the pharmaceutical preparation of the present invention is not limited, and it can be administered according to the dosage form, the age, sex of the patient, differences in other conditions, the degree of symptoms, and the like.
- tablets, pills, solutions, suspensions, emulsions, granules, and capsules are administered orally.
- Injectable preparations can be administered intravascularly, either alone or in combination with conventional infusion solutions (such as glucose or hydroacid solutions). If necessary, they can be administered intramuscularly, intradermally, subcutaneously, or intraperitoneally. Dosing. Suppositories are administered rectally.
- the dosage of the pharmaceutical preparation of the present invention can be appropriately selected according to the use, the patient's age, gender and other conditions, the degree of symptoms, and the like.
- Anemarrhena is the rhizome of Anemarrhena asphodeloides Bge., A plant of the Liliaceae family.
- Anemarrhena asphodeloides was 3 Kg, and extracted with 90% EtOH under reflux for 3 times, and EtOH was recovered under reduced pressure to obtain 700 g of extract.
- the extract was dissolved in water and filtered to obtain an aqueous solution and a water-insoluble portion.
- the water-soluble portion was concentrated and extracted with n-BuOH. ⁇ -BuOH was recovered under reduced pressure to obtain 90 g of extract.
- n-BuOH extract was subjected to silica gel column chromatography, eluting with CHC13-MeOH-H2O (60:35:10 lower layer), 150 ml each, and the more polar fractions 54-62 were combined, and then the silica gel column Chromatographically, the solvent system CHC13-MeOH-H2 0 (60:30:10 lower layer;), CHCI3 -MeOH-H2 0 (55:35:10 lower layer) were sequentially eluted, 100ml each, combined fractions 45-48 The solvent was removed to obtain 1.2 g.
- R3 O-Cal 2 -Glu
- R22 OH
- R2 OH:
- R3 O-Gal 2 -Glu
- R22 OCH 3
- R3 A O-Gal 4 -Glu 2 -Glu
- Compound I is (25S) -26-0- P -D-glucopyranosyl-5 P -furost-20 (22) -ene-3 ⁇ , 26-diol- 3-0- ⁇ glucopyran Glycosyl (1 ⁇ 2) - ⁇ -D-galactopyranoside (timosaponin B).
- FAB-MS m / z 925 (M + Na) +, 903 (M + H) +, 741 (M + H-Glc) +, 579 (M + H-Glc ⁇ 2) +, 417 (M + H- Glc x 3) +, 399 (aglycon + H-H2 0) +, 255, 185, 145.
- Compound II is (25S) -26-0- P -D-glucopyranosyl-5 ⁇ -furost-20 (22) -ene-3 P, 26-diol-3-0- ⁇ -fluorene- Grapepyranosyl (1 ⁇ 2) - ⁇ -D-glucopyranoside (timosaponin C).
- Substance V White amorphous powder, mp 271 "(dec). Liebermann-Burchard reaction and Molish reaction are positive and negative to Ehrlich reagent. IR v max cm” 1 : 3394, 2930, 1070, 988, 919, 896, 847.
- Compound Va is saponin-3-0- ⁇ -D-glucopyranosyl (1 ⁇ 2) [ ⁇ -D-xyranylpyranosyl (1 ⁇ 3)]-P-D-glucopyranosyl (1 ⁇ 4) - ⁇ -D-galactopyranoside (degalactotigonin).
- Compound Vb is neotidin saponin-3-0-P-D-glucopyranosyl (1 ⁇ 2) [P Xyranosyl (1 ⁇ 3)]-P-D-glucopyranosyl (1 ⁇ 4) -P diuranthoside A.
- Substance VI White amorphous powder, mp 247 "C (dec). Liebermaim- Burchard reaction and Molish reaction are positive, negative reaction to Ehrlich reagent.
- IRv max cm" 1 3408, 2931, 2875, 1072, 987, 922, 897,847.
- Compound VI a is a branched saponin-3-0- ⁇ -D-glucopyranosyl group (1 ⁇ 2) [ ⁇ -pyranoxyl (1 ⁇ 3)]-P-D-glucopyranosyl group (1 ⁇ 4)- ⁇ -galactopyranosyl (F-gitonin).
- Compound VI b is neobranyl saponin-3-0- ⁇ -glucopyranosyl (1 ⁇ 2) [ ⁇ -D-xylpyranosyl (1 ⁇ 3)]- ⁇ -glucopyranosyl (1 ⁇ 4 )- ⁇ -D-galactopyranoside (Famosaponin F).
- Substance VII white amorphous powder, mp 242 X. Liebermami-Burchard reaction and Molish reaction were positive and negative to Ehrlich reagent. IR v max cm “ 1 : 3394, 2934, 1069, 985, 919, 896, 847.
- FAB-MS (positive) m / z 1055 (M + Na) +, 1033 (M + H) + , 737 (M- Glc-Xyl-H) + , 577 (M-XyI-Glc ⁇ 2 + H) + , 415 (aglycone + H) + , 397 (aglycone- H 2 0 + H) + .
- EI-MS m / z 414 ( aglycone) + , 396 (agIycone-H 2 0) + , 355, 345, 342, 300, 282, 271, 139.
- Compound VII a is diosgenin-3-0- ⁇ -glucopyranosyl (1 ⁇ 2) [ ⁇ -D-xylpyranosyl (1 ⁇ 3)]- ⁇ - ⁇ -glucopyranosyl (1 ⁇ 4)- ⁇ - ⁇ -galactopyranoside (aspidistrin).
- ⁇ C-MR ⁇ data are shown in Table 2.
- Compound VII b is samogenin-3-0- ⁇ -D-glucopyranosyl (1-2) [P xyloxypyranosyl (1 ⁇ 3)]-P -D-glucopyranosyl (1 ⁇ 4)- ⁇ -D- galactose (3-0-P-lycotetrasoyI yamogenin).
- Substance VIII white amorphous powder, mp 258 (dec). Liebermann-Burchard reaction and Molish reaction were positive and negative to Ehrlich reagent. IRv max cm “ 1 : 3414, 2940, 2902, 1071, 988, 920, 895,849.
- EI-MS m / z 430 (aglycone) + , 413 (aglycone-H 2 0 + H) + , 412 (agIycone-H 2 0) + , 371, 361, 358, 316,298, 287, 269, 139, 126, 115.
- Compound VIII a is Yucca saponin-3-0- ⁇ -D-glucopyranosyl (1 ⁇ 2) [P Xyranosyl (1 ⁇ 3)]-P-D-glucopyranosyl (1 ⁇ 4)- ⁇ -galactopyranoside (karatavioside A).
- ⁇ C-NMR spectrum data are shown in Table 2.
- Compound VIII b is lirasaponin-3-0- ⁇ -D-glucopyranosyl (1 ⁇ 2) [P Xyloxypyranosyl (1 ⁇ 3)]-P-D-glucopyranosyl (1 ⁇ 4)- ⁇ -D-galactopyranoside (timosaponin G).
- OCH 3 47.4 Pharmacology Alzheimer's disease is a group of unexplained progressive mental failure in neurology Degenerative disorders, the cause of which is more complex. The inventors observed timosaponin from multiple angles, among which is compound III, the activity of preventing and treating senile dementia. I. Effects on animal brain circulation metabolism:
- Rats were sacrificed, thoracic aorta was removed, connective tissue and blood were removed, and immersion Krebs-Henseleit solution, oxygenated, hung on the transducer, and measured the radial tension. The results are shown in Figure 1.
- compound III can also inhibit the contraction of rat aorta caused by KC1.
- Apparatus LS-III tissue blood flow meter.
- the animals were anesthetized with 10% chlorine hydrate, the common femoral vein was isolated and cannulated.
- AD Alzheimer's dementia
- SY-SY5Y is a human neuroblastoma cell that expresses natural N and M receptors, while M10 cells express the a4b2 subtype of recombinant chicken N receptor.
- Two cell lines were treated with a series of compounds III at different concentrations, and the amount of N receptor was determined three days later. The results are shown in Figures 3 and 4.
- Free radical reactions are now thought to cause damage to the structure and function of central nervous cell membranes An important factor, people are also developing some free radical scavengers as anti-dementia drugs. Scavenging effect of saponins from timosaponin on free radicals was observed by paramagnetic method.
- the saponin was put into a quartz capillary immediately after mixing the hooks, and measured after 1 minute.
- ho is the peak height of the ESR wave in the control system
- hx is the height of the corresponding peak after dosing.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002304770A CA2304770C (en) | 1997-09-26 | 1998-09-28 | A use of steroidal saponins for the prophylaxis or treatment of dementia, and novel steroidal saponin compounds |
EP98946213A EP1024146B1 (en) | 1997-09-26 | 1998-09-28 | Use of a steroid saponin for the treatment of dementia |
JP2000513868A JP4338306B2 (ja) | 1997-09-26 | 1998-09-28 | 痴呆の予防または治療のためのステロイドサポニンの使用、及び新規なステロイドサポニン化合物 |
US09/509,287 US6593301B1 (en) | 1997-09-26 | 1998-09-28 | Use of steroidal saponins for the prophylaxis or treatment of dementia, and novel steroidal saponin compounds |
AU93360/98A AU9336098A (en) | 1997-09-26 | 1998-09-28 | The use of steroid saponin compounds to prevent senility, and novel steroid saponin compounds |
DE69841421T DE69841421D1 (de) | 1997-09-26 | 1998-09-28 | Die verwendung von einem steroidsaponin zur behandlung von demenz |
KR1020007003288A KR100354826B1 (ko) | 1997-09-26 | 1998-09-28 | 스테로이드성 사포닌을 이용한 치매의 예방 치료와스테로이드성 사포닌 화합물 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97119680A CN1131237C (zh) | 1997-09-26 | 1997-09-26 | 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙 |
CN97119680.X | 1997-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999016786A1 true WO1999016786A1 (fr) | 1999-04-08 |
Family
ID=5175496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN1998/000204 WO1999016786A1 (fr) | 1997-09-26 | 1998-09-28 | Utilisation de composes de saponine et de steroides pour prevenir la senilite et nouveaux composes de saponine steroide |
Country Status (9)
Country | Link |
---|---|
US (1) | US6593301B1 (zh) |
EP (1) | EP1024146B1 (zh) |
JP (1) | JP4338306B2 (zh) |
KR (1) | KR100354826B1 (zh) |
CN (1) | CN1131237C (zh) |
AU (1) | AU9336098A (zh) |
CA (1) | CA2304770C (zh) |
DE (1) | DE69841421D1 (zh) |
WO (1) | WO1999016786A1 (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2335599A (en) * | 1998-03-26 | 1999-09-29 | Phytopharm Plc | Treatment of conditions characterised by a deficiency in the number and function of membrane bound receptors using saponins and sapogenins |
US6258386B1 (en) | 1999-03-08 | 2001-07-10 | Phytopharm Plc | Smilagenin and its use |
WO2001049703A3 (en) * | 2000-01-06 | 2002-02-21 | Phytopharm Plc | Substituted sapogenins and their use |
JP2003510332A (ja) * | 1999-09-29 | 2003-03-18 | ファイトファーム・ピーエルシー | 5−β−サポゲニン及び擬サポゲニン誘導体、並びに痴呆の治療におけるその用途 |
JP2003510333A (ja) * | 1999-09-29 | 2003-03-18 | ファイトファーム・ピーエルシー | サポゲニン誘導体及び認知機能障害の治療におけるその用途 |
JP2003525869A (ja) * | 1999-09-29 | 2003-09-02 | ファイトファーム・ピーエルシー | 抗痴呆活性を有する5−ヒドロキシサポゲニン |
JP2005528370A (ja) * | 2002-03-27 | 2005-09-22 | フィトファーム・パブリック・リミテッド・カンパニー | 治療方法ならびにサポゲニンおよびその誘導体の使用 |
US7166308B2 (en) | 1999-03-08 | 2007-01-23 | Zongqin Xia | Smilagenin and its use |
JP2010031034A (ja) * | 2002-03-27 | 2010-02-12 | Phytopharm Plc | 治療方法ならびにサポゲニンおよびその誘導体の使用 |
WO2010084356A1 (en) | 2009-01-24 | 2010-07-29 | Phytopharm Plc | Treatment of neurotrophic factor mediated disorders |
KR101130212B1 (ko) * | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030118673A1 (en) * | 1998-03-26 | 2003-06-26 | Zongqin Xia | Smilagenin and anzurogenin-D for the treatment of alzheimer's disease |
CN1422861A (zh) * | 2001-12-03 | 2003-06-11 | 张晓� | 皂甙化合物的用途 |
WO2003077869A2 (en) * | 2002-03-15 | 2003-09-25 | Samaritan Pharmaceuticals, Inc | Neuroprotective spirostenol pharmaceutical compositions |
US20050130948A1 (en) * | 2002-03-27 | 2005-06-16 | Daryl Rees | Therapeutic methods and uses of sapogenins and their derivatives |
RU2332999C2 (ru) * | 2002-03-27 | 2008-09-10 | ФИТОФАРМ ПиЭлСи | Терапевтические способы и применения сапогенинов и их производных |
US20060009433A1 (en) * | 2003-03-14 | 2006-01-12 | Zhi-Xing Yao | Neuroprotective spirostenol pharmaceutical compositions |
GB0513881D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
GB0329667D0 (en) * | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
US20080182801A1 (en) | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
CN100427500C (zh) * | 2004-04-29 | 2008-10-22 | 中国人民解放军军事医学科学院放射医学研究所 | 知母皂苷bⅱ的制备方法 |
CN1692914B (zh) | 2004-04-29 | 2010-05-26 | 中国人民解放军军事医学科学院放射医学研究所 | 知母皂苷bⅱ在制备用于防治脑卒中药物或产品中的用途 |
CN1315866C (zh) * | 2004-05-09 | 2007-05-16 | 上海正祥天然药物科技有限公司 | 天冬总甾体皂苷提取物及其制备方法与应用 |
CN1732955B (zh) * | 2004-08-03 | 2011-02-09 | 山东绿叶制药有限公司 | 以知母总皂苷元为活性成分的药物组合物及其制备方法和用途 |
CN1754541A (zh) * | 2004-09-30 | 2006-04-05 | 成都地奥制药集团有限公司 | 甾体皂苷药物组合物及其制备方法和用途 |
AU2005295617A1 (en) * | 2004-10-14 | 2006-04-27 | Georgetown University | Neuroprotective spirostenol pharmaceutical compositions |
BRPI0611528A2 (pt) * | 2005-05-17 | 2010-11-23 | Satori Pharmaceuticals Inc | compostos úteis para tratamento de distúrbios neurodegenerativos |
GB0512726D0 (en) * | 2005-06-22 | 2005-07-27 | Btg Int Ltd | Multiple sclerosis therapy and diagnosis |
GB0513888D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
WO2007049932A1 (en) * | 2005-10-28 | 2007-05-03 | Sun-Yeou Kim | Extract of the family dioscoreaceae and composition for preventing or treating peripheral neuropathy comprising the same |
US20110054156A1 (en) * | 2008-04-30 | 2011-03-03 | Institute Of Radiation Medicine, Academy Of Military Sciences, Pla | Synthesis of timosaponin bii |
CN102311481B (zh) * | 2010-07-01 | 2012-12-05 | 中国科学院上海药物研究所 | 毛红椿酸甲酯及其制备方法和用途 |
BR112013001422A2 (pt) | 2010-07-20 | 2019-09-24 | Phytopharm Plc | metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson |
KR101341693B1 (ko) * | 2011-03-16 | 2013-12-16 | 동아에스티 주식회사 | 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물 |
WO2013149580A1 (en) * | 2012-04-03 | 2013-10-10 | Chiming Che | Timosaponin compounds |
KR101777920B1 (ko) | 2015-07-27 | 2017-09-14 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | 진세노사이드 f1을 포함하는 아밀로이드 플라크 제거용 조성물 |
CN105153266B (zh) * | 2015-07-30 | 2017-03-22 | 中国人民解放军第四军医大学 | 一种甾体皂苷类化合物及其在制备抗肿瘤药物中的应用 |
WO2017064530A1 (en) * | 2015-10-16 | 2017-04-20 | Instituto Tecnológico y de Estudios Superiores de Monterrey | Agavaceae extract comprising steroidal saponins to treat or prevent metabolic disorder related pathologies |
CN105440098B (zh) * | 2015-12-31 | 2017-04-19 | 南京中医药大学 | 一种制备知母皂苷n的方法 |
CN107488204A (zh) * | 2017-08-17 | 2017-12-19 | 烟台大学 | 达玛烷型人参皂苷(元)及其ocotillol型衍生物的抗炎用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0054570A1 (en) * | 1980-03-05 | 1982-06-30 | Zenyaku Kogyo Kabushiki Kaisha | Novel condurango glycosides, process for their preparation, antineoplastic agent, and composition containing same |
WO1997031933A1 (en) * | 1996-02-27 | 1997-09-04 | Cheil Je Dang Co. | Novel ginseng saponin compounds, process for preparation thereof and anti-tumor agent comprising the same as an active component |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2631686B2 (ja) * | 1988-03-01 | 1997-07-16 | 湧永製薬株式会社 | 新規ステロイドサポニンおよびその製造法ならびにこれらの誘導体の新規用途 |
JPH02243631A (ja) * | 1989-03-15 | 1990-09-27 | Wakunaga Pharmaceut Co Ltd | 抗発癌プロモーター |
JPH0454194A (ja) * | 1990-06-19 | 1992-02-21 | Wakunaga Pharmaceut Co Ltd | 新規ステロイド配糖体およびこの製造法ならびにこれを有効成分とする血糖降下剤 |
CN1088748A (zh) * | 1993-01-01 | 1994-07-06 | 赵广才 | 荞麦保健食品 |
DE4303214A1 (de) * | 1993-02-04 | 1994-08-11 | Wolfgang Marks | Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone |
US5502038A (en) * | 1993-06-21 | 1996-03-26 | Medical Research Foundation Of Oregon | Cholesterol sequestrant glycosides that inhibit intestinal cholesterol absorption |
CN1102186A (zh) * | 1993-10-29 | 1995-05-03 | 沈阳医学院 | 中药薤白新成分的鉴定及用途 |
JPH07267864A (ja) * | 1994-03-28 | 1995-10-17 | Tsumura & Co | 体温降下剤 |
JPH0859476A (ja) * | 1994-08-22 | 1996-03-05 | Shiratori Seiyaku Kk | 肝炎治療剤 |
CN1138984A (zh) * | 1995-06-26 | 1997-01-01 | 军事医学科学院放射医学研究所 | 新型甙类抗血栓药物 |
-
1997
- 1997-09-26 CN CN97119680A patent/CN1131237C/zh not_active Expired - Lifetime
-
1998
- 1998-09-28 DE DE69841421T patent/DE69841421D1/de not_active Expired - Lifetime
- 1998-09-28 JP JP2000513868A patent/JP4338306B2/ja not_active Expired - Fee Related
- 1998-09-28 KR KR1020007003288A patent/KR100354826B1/ko active IP Right Review Request
- 1998-09-28 WO PCT/CN1998/000204 patent/WO1999016786A1/zh active IP Right Grant
- 1998-09-28 US US09/509,287 patent/US6593301B1/en not_active Expired - Lifetime
- 1998-09-28 AU AU93360/98A patent/AU9336098A/en not_active Abandoned
- 1998-09-28 EP EP98946213A patent/EP1024146B1/en not_active Expired - Lifetime
- 1998-09-28 CA CA002304770A patent/CA2304770C/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0054570A1 (en) * | 1980-03-05 | 1982-06-30 | Zenyaku Kogyo Kabushiki Kaisha | Novel condurango glycosides, process for their preparation, antineoplastic agent, and composition containing same |
WO1997031933A1 (en) * | 1996-02-27 | 1997-09-04 | Cheil Je Dang Co. | Novel ginseng saponin compounds, process for preparation thereof and anti-tumor agent comprising the same as an active component |
Non-Patent Citations (1)
Title |
---|
See also references of EP1024146A4 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6812213B2 (en) * | 1998-03-26 | 2004-11-02 | Phytopharm, Plc | Steroidal sapogenins and their derivatives for treating alzheimer's disease |
WO1999048507A2 (en) * | 1998-03-26 | 1999-09-30 | Phytopharm Plc | Steroidal saponins for treating alzheimer's disease |
WO1999048482A2 (en) * | 1998-03-26 | 1999-09-30 | Phytopharm Plc | Smilagenin and anzurogenin-d for the treatment of alzheimer's disease |
WO1999048507A3 (en) * | 1998-03-26 | 1999-11-25 | Phytopharm Plc | Steroidal saponins for treating alzheimer's disease |
WO1999048482A3 (en) * | 1998-03-26 | 2000-11-23 | Phytopharm Plc | Smilagenin and anzurogenin-d for the treatment of alzheimer's disease |
US7507720B2 (en) | 1998-03-26 | 2009-03-24 | Phytopharm Plc | 5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
GB2335599A (en) * | 1998-03-26 | 1999-09-29 | Phytopharm Plc | Treatment of conditions characterised by a deficiency in the number and function of membrane bound receptors using saponins and sapogenins |
US6258386B1 (en) | 1999-03-08 | 2001-07-10 | Phytopharm Plc | Smilagenin and its use |
US7368137B2 (en) | 1999-03-08 | 2008-05-06 | Phytopharm Plc | Smilagenin and its use |
US7166308B2 (en) | 1999-03-08 | 2007-01-23 | Zongqin Xia | Smilagenin and its use |
US7138427B2 (en) | 1999-03-26 | 2006-11-21 | Phytopharm Plc. | 5-β-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
EP1548025A3 (en) * | 1999-09-29 | 2008-11-19 | Phytopharm Plc | Sapogenin derivatives and their use in the treatment of cognitive dysfunction |
JP2003510332A (ja) * | 1999-09-29 | 2003-03-18 | ファイトファーム・ピーエルシー | 5−β−サポゲニン及び擬サポゲニン誘導体、並びに痴呆の治療におけるその用途 |
CZ300150B6 (cs) * | 1999-09-29 | 2009-02-25 | Phytopharm Plc | Lécivo pro zlepšení kognitivní funkce nebo léceníkognitivní dysfunkce |
JP2003525869A (ja) * | 1999-09-29 | 2003-09-02 | ファイトファーム・ピーエルシー | 抗痴呆活性を有する5−ヒドロキシサポゲニン |
EP1548025A2 (en) * | 1999-09-29 | 2005-06-29 | Phytopharm Plc | Sapogenin derivatives and their use in the treatment of cognitive dysfunction |
KR100771491B1 (ko) * | 1999-09-29 | 2007-10-30 | 파이토팜 피엘씨 | 5-β-사포게닌 및 유사 사포게닌 유도체 및 치매치료에서의 이들의 사용법 |
JP2003510333A (ja) * | 1999-09-29 | 2003-03-18 | ファイトファーム・ピーエルシー | サポゲニン誘導体及び認知機能障害の治療におけるその用途 |
JP2003519624A (ja) * | 2000-01-06 | 2003-06-24 | ファイトファーム・ピーエルシー | 置換サポゲニン及びそれらの使用 |
WO2001049703A3 (en) * | 2000-01-06 | 2002-02-21 | Phytopharm Plc | Substituted sapogenins and their use |
JP2005528370A (ja) * | 2002-03-27 | 2005-09-22 | フィトファーム・パブリック・リミテッド・カンパニー | 治療方法ならびにサポゲニンおよびその誘導体の使用 |
JP2010031034A (ja) * | 2002-03-27 | 2010-02-12 | Phytopharm Plc | 治療方法ならびにサポゲニンおよびその誘導体の使用 |
KR101130212B1 (ko) * | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
JP2013053163A (ja) * | 2002-03-27 | 2013-03-21 | Phytopharm Plc | 治療方法ならびにサポゲニンおよびその誘導体の使用 |
WO2010084356A1 (en) | 2009-01-24 | 2010-07-29 | Phytopharm Plc | Treatment of neurotrophic factor mediated disorders |
Also Published As
Publication number | Publication date |
---|---|
CN1131237C (zh) | 2003-12-17 |
US6593301B1 (en) | 2003-07-15 |
EP1024146A1 (en) | 2000-08-02 |
CA2304770C (en) | 2009-01-20 |
JP2001518477A (ja) | 2001-10-16 |
KR20010030746A (ko) | 2001-04-16 |
AU9336098A (en) | 1999-04-23 |
DE69841421D1 (de) | 2010-02-11 |
EP1024146B1 (en) | 2009-12-30 |
KR100354826B1 (ko) | 2002-10-05 |
EP1024146A4 (en) | 2006-02-08 |
CN1212966A (zh) | 1999-04-07 |
JP4338306B2 (ja) | 2009-10-07 |
CA2304770A1 (en) | 1999-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999016786A1 (fr) | Utilisation de composes de saponine et de steroides pour prevenir la senilite et nouveaux composes de saponine steroide | |
JP3553086B2 (ja) | 食欲抑制活性を有する医薬組成物 | |
EP1169336B1 (en) | Ent-steroids as selectively active estrogens | |
CN109575099B (zh) | 达玛烷皂苷元衍生物及其制备方法和应用 | |
TWI422377B (zh) | 用於促進抗癌治療活性之方法及組成物 | |
CN102172357A (zh) | 核心2glcnac-t抑制剂 | |
CN106967147B (zh) | C27螺甾烷型甾体皂苷化合物与其药物组合物和其应用 | |
CN104910240B (zh) | 光叶子花中三萜皂苷,以其为活性成分的降血糖药物,及其制备方法和应用 | |
TW201623208A (zh) | 牛樟芝化合物、製備方法及其用途 | |
CN101775061A (zh) | 一组苦丁茶皂苷类化合物 | |
CN101119740B (zh) | 中药地榆及其提取物在制备升高红细胞和血红蛋白药物中的应用 | |
CN103739647A (zh) | 用于治疗疾病的NF-κB的非激素甾体调节剂 | |
WO2006063515A1 (fr) | Utilisation de radix sanguisorbae et de son extrait pour la preparation d’un medicament visant a accroitre la numeration erythrocytaire et le taux d’hemoglobine | |
JP2020506909A (ja) | トチバニンジン属植物の抽出物およびその薬物組成物と使用 | |
CN101309692A (zh) | 葫芦素或葫芦素组合物在制备提高白细胞的药物中的应用 | |
CN100357309C (zh) | 一种具有免疫抑制作用的碳-21甾体苷 | |
KR100564383B1 (ko) | 진세노사이드 유도체의 제조방법 | |
CN107056877B (zh) | 一种甾体类化合物及其用途 | |
US10391104B2 (en) | Application of antidepressant compound in preparation of antidepressant drugs and antidepressant health-care foods | |
KR100547253B1 (ko) | 암 예방 및 치료에 유효한 진세노사이드 유도체 | |
KR101237898B1 (ko) | 암 전이 억제용 조성물 | |
CN105669818A (zh) | 头孢唑林钠的药物组合物及其在生物医药中的应用 | |
EP1591123B1 (en) | Uses of naringenin, naringin and salts thereof as expectorants in the treatment of cough, and compositions thereof | |
JP2001253823A (ja) | Hiv遺伝子発現抑制剤 | |
JP2008137985A (ja) | 副腎皮質ホルモン剤の副作用を増強させることなく、抗アレルギー効果を増強する薬剤、及び副腎皮質ホルモン剤の副作用を増強させることなく、抗アレルギー効果を増強させる方法。 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2304770 Country of ref document: CA Kind code of ref document: A Ref document number: 2304770 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007003288 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998946213 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09509287 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998946213 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007003288 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007003288 Country of ref document: KR |